A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
Georgia Schilling,Timon Hansen,Avichai Shimoni,Tatjana Zabelina,J. A. Simon-Perez,Norma C. Gutiérrez,Wolfgang Bethge,Peter Liebisch,Rainer Schwerdtfeger,Martin Bornhäuser,Svenja Otterstetter,Eva Maria Murga Penas,Judith Dierlamm,Francis Ayuk,Djordje Atanackovic,Ulrike Bacher,Carsten Bokemeyer,Axel R. Zander,Jesus-Fernando San Miguel,Arnon Nagler,N Kröger +20 more
TL;DR: It is shown that del(17p13) is a negative prognostic factor for achieving CR as well as for event-free survival after HSCT and might be overcome by allogeneic HSCT, which will have implication for risk-adapted strategies.
Journal ArticleDOI
Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse
Mohamed A. Kharfan-Dabaja,Myriam Labopin,Emmanuelle Polge,Taiga Nishihori,Ali Bazarbachi,Jürgen Finke,Michael Stadler,Gerhard Ehninger,Bruno Lioure,Nicolaas Schaap,Boris V. Afanasyev,Moshe Yeshurun,Cecilia Isaksson,Johan Maertens,Yves Chalandon,Christoph Schmid,Arnon Nagler,Mohamad Mohty +17 more
TL;DR: Findings of this study highlight that best outcomes seem to be achieved in patients relapsing 6 or more months from an allo-HCT1 or those in complete remission at the time of either allo.HCT2 or DLI, regardless of the treatment prescribed.
Journal ArticleDOI
The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma
Amnon Peled,Michal Abraham,Irit Avivi,Jacob M. Rowe,Katia Beider,Hanna Wald,Lena Tiomkin,Lena Ribakovsky,Yossi Riback,Yaron Ramati,Sigal Aviel,Eithan Galun,Howard Laurence Shaw,Orly Eizenberg,Izhar Hardan,Avichai Shimoni,Arnon Nagler +16 more
TL;DR: When combined with G-CSF, BKT140 is a safe and efficient stem cell mobilizer that enabled the collection of a high number of CD34+ cells in 1 and 2 aphaeresis procedures, resulting in successful engraftment.
Journal ArticleDOI
Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy.
Vanderson Rocha,Stephen R. Spellman,Mei-Jie Zhang,Annalisa Ruggeri,Duncan Purtill,Colleen Brady,Lee Ann Baxter-Lowe,Etienne Baudoux,Paola Bergamaschi,Robert Chow,Brian M. Freed,Gesine Koegler,Joanne Kurtzberg,Jérôme Larghero,Lucilla Lecchi,Arnon Nagler,Cristina Navarrette,Vinod K. Prasad,Fabienne Pouthier,Thomas H. Price,Voravit Ratanatharathorn,Jon J. van Rood,Mary M. Horowitz,Eliane Gluckman,Mary Eapen +24 more
TL;DR: When faced with the choice of multiple HLA-mismatched UCB units containing adequate cell doses, selecting an NIMA-matched UCB unit may improve survival after mismatched UCBT.
Journal ArticleDOI
Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.
TL;DR: The combination of fludarabine and treosulfan was explored in several studies in patients not eligible for standard myeloablative conditioning, and data are rapidly emerging that resulted in favorable survival in the range of 40–80%.